SCHEMBL23928155

SCHEMBL23928155

NCCc1ccc(NCC2COC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 10/20 0.37
▸ HTR2A P28223 4/20 0.37
▸ CYP2A6 P11509 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HTR3A P46098 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ HTR6 P50406 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ LOXL2 Q9Y4K0 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MAOB P27338 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17845233 0.79 MAPT (0.43) KDM4EALDH1A1L3MBTL1BLMKMT2A
SCHEMBL23928114 0.76 TAAR1 (0.39) TAAR1HTR2ACYP2A6CYP1A2KDM4E
SCHEMBL28184974 0.72 CA2 (0.50) CA12CA1CA2CA4CA6
SCHEMBL22681016 0.71 CA1 (0.38) KDM4EALDH1A1SLC6A2KMT2ASMN1; SMN2
SCHEMBL15599543 0.69 TAAR1 (0.52) TAAR1HTR2ACYP2A6CYP1A2KDM4E
SCHEMBL20969746 0.69 TAAR1 (0.58) TAAR1HTR2ACYP2A6CYP1A2KDM4E
SCHEMBL17852320 0.68 TRPC5 (0.48) KDM4EALDH1A1BACE1L3MBTL1BLM
SCHEMBL23928127 0.68 BACE1 (0.40) TAAR1HTR2ACYP2A6CYP1A2KDM4E
SCHEMBL1459468 0.67 TAAR1 (0.54) TAAR1HTR2ACYP2A6CYP1A2KDM4E
SCHEMBL23928198 0.67 RORC (0.42) TAAR1HTR2ACYP2A6CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 — — EP disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 — — US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 — — US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 — — CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 — — US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 TAAR1 36/4885HTR2A 7/4885CYP2A6 1454/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 TAAR1 36/4885HTR2A 7/4885CYP2A6 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback